[1] 王爱平,王若珺,李若瑜.抗真菌药物新进展[J].皮肤科学通报,2017,34(5):540-550,504.
[2] Krasulova K, Dvorak Z, Anzenbacher P. In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes:stereoselective inhibition of CYP3A[J]. Xenobiotica, 2018:1-7. DOI:10.1080/00498254.2018.1425510.
[3] 王爱平,李若瑜.伊曲康唑胶囊上市16周年安全性资料回顾[J].中国真菌学杂志,2010,5(1):40-43.
[4] Kao WY, Su CW, Huang YS, et al. Risk of oral antifungal agent-induced liver injury in Taiwanese[J]. Br J Clin Pharmacol, 2014, 77(1):180-189.
[5] Paul V, Rawal H. Cardiotoxicity with itraconazole[J]. BMJ Case Rep, 2017,pii:bcr-2017-219376.
[6] Salem M,Reichlin T,Fasel D,et al. Torsade de pointes and systemic azole antifungal agents:analysis of global spontaneous safety reports[J]. Glob Cardiol Sci Pract,2017(2):11.
[7] de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, et al. Treatment of cutaneous sporotrichosis with itraconazole-study of 645 patients[J]. Clin Infect Dis, 2011, 52(12):e200-206.
[8] Queiroz-Telles F, Goldani LZ, Schlamm HT,et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis[J]. Clin Infect Dis, 2007, 45(11):1462-1469.
[9] Chen S, Sun KY, Feng XW, et al. Efficacy and safety of itraconazole use in infants[J]. World J Pediatr, 2016, 12(4):399-407.
[10] Bar-Oz B, Moretti ME, Mareels G, et al. Reporting bias in retrospective ascertainment of drug-induced embryopathy[J]. Lancet, 1999, 354(9191):1700-1701.
[11] Bar-Oz B,Moretti ME,Bishai R.et al. Pregnancy outcome after in utero exposure to itraconazole:a prospective cohort study[J]. Am J Obstet Gynecol,2000183(3):617-620.
[12] De Santis M,Di Gianantonio E,Cesari E.et al. First-trimester itraconazole exposure and pregnancy outcome:a prospective cohort study of women contacting teratology information services in Italy[J]. Drug Saf,2009,32(3):239-244.
[13] 聂舒, 缪飞, 王宏伟,等. 小剂量伊曲康唑治疗老年甲真菌病临床研究[J]. 中国麻风皮肤病杂志, 2017, 33(6):365-366.
[14] 徐精彩,毕丽珠.伊曲康唑治疗老年肺部真菌感染患者46例[J].现代中西医结合杂志,2007(35):5311-5312.
[15] 孙文萍,关望,宋丽清,等.伊曲康唑治疗老年肺部真菌感染的疗效与安全性分析[J].中华医院感染学杂志,2012,22(3):592-594.
[16] 刘神幼, 郑红艳, 张琳玲,等. 伊曲康唑治疗老年患者肺部侵袭性真菌感染42例分析[J]. 中国误诊学杂志, 2008, 8(34):8486-8487.
[17] 纪宇, 许兰平, 黄晓军. 伊曲康唑在化疗及造血干细胞移植患者不同治疗策略中的疗效和安全性分析[J]. 中华血液学杂志, 2014, 35(8):689-693.
[18] 储金华, 王宁玲, 涂松济. 伊曲康唑预防急性白血病患儿侵袭性真菌感染的临床研究[J]. 中国小儿血液与肿瘤杂志, 2014,19(4):207-209.
[19] 秦铁军, 杨栋林, 李睿,等. 静脉伊曲康唑治疗恶性血液病患者侵袭性真菌感染临床研究[J]. 中华内科杂志, 2005, 44(12):55-56.
[20] 罗晓,邵宏.伊曲康唑治疗EICU侵袭性真菌感染的疗效与安全性分析[J]. 中国药学(英文版),2015,24(10):678-682.
[21] 金林峰,连江山,叶萍.伊曲康唑治疗肝衰竭合并侵袭性肺部真菌感染患者的疗效和安全性分析[J].中国微生态学杂志,2013,25(8):946-948.